As the U.S. stock market enters December 2024, investors are witnessing record highs for the S&P 500 and Nasdaq Composite, marking a robust period of growth following significant gains in November. Amid this backdrop, penny stocks—often associated with smaller or newer companies—remain an intriguing investment option due to their potential for substantial growth at lower price points. While traditionally considered speculative, those penny stocks with strong financials can offer unique opportunities for investors seeking promising under-the-radar companies poised for long-term success.
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.80 | $5.81M | ★★★★★★ |
Inter & Co (NasdaqGS:INTR) | $4.62 | $2.03B | ★★★★☆☆ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $136.98M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.2408 | $8.86M | ★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) | $1.59 | $52.47M | ★★★★★★ |
PHX Minerals (NYSE:PHX) | $3.81 | $142.8M | ★★★★★☆ |
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) | $1.30 | $65.6M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.9429 | $84.8M | ★★★★★☆ |
Safe Bulkers (NYSE:SB) | $3.87 | $413.23M | ★★★★☆☆ |
Click here to see the full list of 708 stocks from our US Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: KORU Medical Systems, Inc. develops and manufactures medical devices and supplies for both the United States and international markets, with a market cap of $182.43 million.
Operations: The company's revenue is derived from its Surgical & Medical Equipment segment, totaling $31.99 million.
Market Cap: $182.43M
KORU Medical Systems, with a market cap of US$182.43 million, recently raised its full-year earnings guidance, expecting revenue between US$32.75 million and US$33.25 million—up from previous estimates. Despite this positive outlook and a stable cash runway exceeding three years, the company remains unprofitable with increasing losses over five years at a rate of 50.6% annually. Its short-term assets cover both short- and long-term liabilities comfortably, though it faces challenges in achieving profitability within the next three years as forecasted revenues grow at 14.74% per year amidst stable weekly volatility.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: SOPHiA GENETICS SA is a cloud-native software technology company in the healthcare sector with a market cap of $226.56 million.
Operations: The company generates revenue from its healthcare software segment, which amounts to $64.49 million.
Market Cap: $226.56M
SOPHiA GENETICS, with a market cap of US$226.56 million, shows potential in the healthcare software sector despite current unprofitability and increased losses over five years. The company has a seasoned management team and board, with short-term assets surpassing both short- and long-term liabilities. Recent executive changes include Ross Muken's promotion to President and George Cardoza as CFO, bringing extensive industry experience. Revenue is forecasted to grow 16.65% annually, although profitability remains elusive for the next three years. The stock trades significantly below estimated fair value, while analysts predict a substantial price increase potential of 76%.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Verde Resources, Inc. operates through its subsidiaries in the production of biochar from waste materials in the dairy, palm, and other natural resource industries across the United States and Malaysia, with a market cap of $198.68 million.
Operations: Verde Resources generates revenue through the production of biochar from waste materials in the dairy, palm, and other natural resource sectors within the United States and Malaysia.
Market Cap: $198.68M
Verde Resources, with a market cap of US$198.68 million, operates in the biochar production sector but remains pre-revenue with sales under US$1 million. The company faces financial challenges, highlighted by auditor concerns over its ability to continue as a going concern and repeated delays in SEC filings. Despite these hurdles, Verde has made strategic advancements through partnerships like the one with Nature Plus Inc., aiming to innovate soil stabilization methods that reduce environmental impact and costs. However, Verde's high share price volatility and shareholder dilution reflect ongoing instability in its financial positioning.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Discover if KORU Medical Systems might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.